Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02006914 · ClinicalTrials.gov registry record
Novel Therapy for Glucose Intolerance in HIV Disease
A clinical trial of Insulin Resistance, sponsored by Stony Brook University.
- Completed
- Registry status
- 47
- Enrollment target
- 1
- Study location
NCT02006914: Completed study of Insulin Resistance, sponsored by Stony Brook University.
NCT02006914 is a study of Insulin Resistance that has completed, run by Stony Brook University. The registered enrollment target is 47 participants, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (81% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02006914, a study of Insulin Resistance, has completed, sponsored by Stony Brook University.
- COMPLETED
- Registry status
- 47 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is to investigate the nutritional supplement chromium picolinate. The investigators are testing to see how effective this supplement is in treating insulin resistance associated with HIV disease.
Primary Outcome
Hypothesis that chromium picolinate improved insulin-stimulated glucose uptake by increasing the insulin receptor-mediated tyrosine phosphorylation of insulin receptor substrate-1, resulting in increased association with phosphatidylinositol 3-kinase. There was a significant negative correlation between the fasting glucose levels and the insulin sensitivity.
Conditions Studied
Interventions
- DIETARY_SUPPLEMENT Chromium Picolinate
Study Locations (1)
New York
- Stony Brook University Hospital GCRC - Stony Brook
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 47 participants |
| Start Date | 2005-06 |
| Est. Completion | 2012-04 |
What the finished NCT02006914 record still lists
NCT02006914 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 47 participants, a relatively small participant target, below the 245-participant average among 120 other Insulin Resistance trials with a reported enrollment target (81% lower).
The record links to 1 condition, with Insulin Resistance appearing as the primary indexed condition, and to 1 intervention - of which Chromium Picolinate is the first listed.
NCT02006914 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02006914 about?
NCT02006914 is a clinical study titled "Novel Therapy for Glucose Intolerance in HIV Disease". This research is to investigate the nutritional supplement chromium picolinate. The investigators are testing to see how effective this supplement is in treating insulin resistance associated with HIV disease.
What is the current status of trial NCT02006914?
This trial is currently completed. The enrollment target is 47 participants. The study started on 2005-06. Estimated completion is 2012-04.
What conditions does trial NCT02006914 study?
This clinical trial studies the following conditions: Insulin Resistance.
What interventions are being tested in trial NCT02006914?
The interventions under investigation include: Chromium Picolinate (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT02006914?
This trial is sponsored by Stony Brook University, which has 127 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02006914 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Insulin Resistance
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02006914's enrollment target sits among peer trials
47 64th of 120 higher than 56 of 120 other Insulin Resistance trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Insulin Resistance trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Metabolic Adaptations to Weight Loss With and Without Exercise
RECRUITING · NA
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Longitudinal Multi-Omic Profiles to Reveal Mechanisms of Obesity-Mediated Insulin Resistance
RECRUITING · NA
-
Effect of Weight Loss on Intermuscular Adipose Tissue (IMAT) Signaling
RECRUITING · NA
-
Small Extracellular Vesicles and Insulin Action
RECRUITING · NA
-
Metabolic Effects of Angiotensin-(1-7)
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03313011 · 47 participants
The Neurobiology of Two Distinct Types of Progressive Apraxia of Speech
- NCT03467516 · 47 participants · Phase 2
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Metastatic Uveal Melanoma
- NCT03886662 · 47 participants · Phase 1
A Study of LB-100 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndromes (MDS)
- NCT04013802 · 47 participants · Phase 1
TETRAVI Multivirus CTL for Treatment of EBV, CMV, Adenovirus, and BK Infections Post Allogeneic SCT.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia